Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved

Assunta Bianco; Paolo Maria Rossini; Massimiliano Mirabella

doi:10.1001/jamaneurol.2014.1135

Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved

Assunta Bianco^*
, Paolo Maria Rossini
, Massimiliano Mirabella

^*Corresponding author

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

No abstract available

Original language	English
Pages (from-to)	924-925
Number of pages	2
Journal	JAMA Neurology
Volume	71
Issue number	7
DOIs	https://doi.org/10.1001/jamaneurol.2014.1135
Publication status	Published - 2014

All Science Journal Classification (ASJC) codes

Clinical Neurology

Keywords

Antibodies
Drug Substitution
Female
Humanized
Humans
Immunosuppressive Agents
Male
Monoclonal
Multiple Sclerosis
Propylene Glycols
Sphingosine

Access to Document

10.1001/jamaneurol.2014.1135

Cite this

@article{c2768fa4406b49968680e34353171d27,

title = "Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved",

abstract = "No abstract available",

keywords = "Antibodies, Drug Substitution, Female, Humanized, Humans, Immunosuppressive Agents, Male, Monoclonal, Multiple Sclerosis, Propylene Glycols, Sphingosine, Antibodies, Drug Substitution, Female, Humanized, Humans, Immunosuppressive Agents, Male, Monoclonal, Multiple Sclerosis, Propylene Glycols, Sphingosine",

author = "Assunta Bianco and Rossini, \{Paolo Maria\} and Massimiliano Mirabella",

year = "2014",

doi = "10.1001/jamaneurol.2014.1135",

language = "English",

volume = "71",

pages = "924--925",

journal = "JAMA Neurology",

issn = "2168-6149",

publisher = "American Medical Association",

number = "7",

}

TY - JOUR

T1 - Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved

AU - Bianco, Assunta

AU - Rossini, Paolo Maria

AU - Mirabella, Massimiliano

PY - 2014

Y1 - 2014

N2 - No abstract available

AB - No abstract available

KW - Antibodies

KW - Drug Substitution

KW - Female

KW - Humanized

KW - Humans

KW - Immunosuppressive Agents

KW - Male

KW - Monoclonal

KW - Multiple Sclerosis

KW - Propylene Glycols

KW - Sphingosine

KW - Antibodies

KW - Drug Substitution

KW - Female

KW - Humanized

KW - Humans

KW - Immunosuppressive Agents

KW - Male

KW - Monoclonal

KW - Multiple Sclerosis

KW - Propylene Glycols

KW - Sphingosine

UR - https://publicatt.unicatt.it/handle/10807/62746

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84905460443&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84905460443&origin=inward

U2 - 10.1001/jamaneurol.2014.1135

DO - 10.1001/jamaneurol.2014.1135

M3 - Article

SN - 2168-6149

VL - 71

SP - 924

EP - 925

JO - JAMA Neurology

JF - JAMA Neurology

IS - 7

ER -

Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this